Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) overview
Dravet syndrome, also known as severe myoclonic epilepsy of infancy, is a rare genetic disorder that causes a severe form of epilepsy. It usually starts in the first year of life with prolonged seizures triggered by fever or high temperature. Children with Dravet syndrome have various types of seizures that are difficult to treat with medications. They also have developmental delays, cognitive impairment, behavioral problems, and other neurological symptoms. Dravet syndrome is caused by mutations in the SCN1A gene, which affects the function of sodium channels in the brain. The diagnosis is based on clinical features and genetic testing. There is no cure for Dravet syndrome, but treatments aim to reduce the frequency and severity of seizures and improve the quality of life of patients and families.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
